Minimal Side Effects with New Class of Breast Cancer Drugs
Breast Cancer Drugs : Current trials in development
A third CDK inhibitor is currently undergoing phase III trials, and is expected to be approved within the next year. It is called abemaciclib, and it seeks to abate some of the side effect symptoms experienced by people who have been taking Ibrance. Abemaciclib, along with ribociclib and palbociclib, have all been named “breakthrough therapies” by the reviewers who approve the drugs in the FDA.
